TOP > 外国特許検索 > METHOD FOR INDUCING MACROPHAGES, INDUCER FOR ANTI-INFLAMMATORY MACROPHAGES AND PHARMACEUTICAL COMPOSITION

METHOD FOR INDUCING MACROPHAGES, INDUCER FOR ANTI-INFLAMMATORY MACROPHAGES AND PHARMACEUTICAL COMPOSITION

Foreign code F200010242
File No. (S2019-0118-N0)
Posted date 2020年10月30日
Country 世界知的所有権機関(WIPO)
International application number 2020JP009639
International publication number WO2020184425
Date of international filing 令和2年3月6日(2020.3.6)
Date of international publication 令和2年9月17日(2020.9.17)
Priority data
  • 特願2019-042795 (2019.3.8) JP
Title METHOD FOR INDUCING MACROPHAGES, INDUCER FOR ANTI-INFLAMMATORY MACROPHAGES AND PHARMACEUTICAL COMPOSITION
Abstract This method for inducing macrophages involves culturing macrophages in the presence of exosomes produced from interferon γ-added mesenchymal stem cells, and inducing anti-inflammatory macrophages. This inducer for anti-inflammatory macrophages contains exosomes produced from interferon γ-added mesenchymal stem cells as an effective ingredient. This pharmaceutical composition comprises said inducer.
Outline of related art and contending technology BACKGROUND ART
Mesenchymal stem cells (MSC) can be collected not only from bone marrow but also from medical wastes such as adipose tissue and umbilical cord tissue, have low antigenic properties, can also use other cells, and have various roles such as anti-inflammatory, antifibrosis, angiogenesis, antioxidation, and the like. However, it has been reported that MSC is slightly different depending on the cell type from which MSC is derived, and the properties of MSC are changed when they enter into culture conditions and living bodies, and the mechanism of the effect has not been clarified yet. MSC is expected to act on many immune cells through the production of cytokines, chemokines, growth factors, exosomes, and the like as "conducting cells", but the influence on macrophages is paid attention to the pathology of liver cirrhosis.
So far, the inventors have found that MSC changes the polarity of myeloid-derived cultured macrophages to), also referred to as anti-inflammatory macrophages ("M2 macrophages", thereby acting on fibrogenesis improvement and regeneration promotion during liver cirrhosis, for example, see) Non-Patent Document 1.
However, it is known that most of MSC are delivered to the lungs when administered intravenously and very few of MSC are delivered to the liver. Nevertheless, it is presumed that some MSC expression substance is involved in liver cirrhosis because of showing the above effect on liver cirrhosis, but the detailed mechanism of which substance changes the polarity of macrophages has not been clarified.
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NIIGATA UNIVERSITY
  • Inventor
  • TERAI Syuji
  • TSUCHIYA Atsunori
  • TAKEUCHI Suguru
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close